Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

NCT07265232 is registered in ClinicalTrials.gov with Lantu Biopharma as lead sponsor.

NCT NCT07265232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07265232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).
Lead sponsor
Lantu Biopharma
Phase
Phase 3
Overall status
Withdrawn
Start date
October 15, 2025
Completion date
October 15, 2030
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy (sma)